vs
EXACT SCIENCES CORP（EXAS）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是BOSTON BEER CO INC的1.9倍（$878.4M vs $461.6M），EXACT SCIENCES CORP同比增速更快（23.1% vs -4.1%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -10.7%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
EXAS vs SAM — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$461.6M
营收增速更快
EXAS
高出27.2%
-4.1%
两年增速更快
EXAS
近两年复合增速
-10.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $461.6M |
| 净利润 | $-86.0M | — |
| 毛利率 | 70.1% | 46.4% |
| 营业利润率 | -9.4% | 12.4% |
| 净利率 | -9.8% | — |
| 营收同比 | 23.1% | -4.1% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSAM
| Q1 26 | — | $461.6M | ||
| Q4 25 | $878.4M | $385.7M | ||
| Q3 25 | $850.7M | $537.5M | ||
| Q2 25 | $811.1M | $587.9M | ||
| Q1 25 | $706.8M | $453.9M | ||
| Q4 24 | $713.4M | $402.3M | ||
| Q3 24 | $708.7M | $605.5M | ||
| Q2 24 | $699.3M | $579.1M |
净利润EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | $-86.0M | $-22.5M | ||
| Q3 25 | $-19.6M | $46.2M | ||
| Q2 25 | $-1.2M | $60.4M | ||
| Q1 25 | $-101.2M | $24.4M | ||
| Q4 24 | $-864.6M | $-38.8M | ||
| Q3 24 | $-38.2M | $33.5M | ||
| Q2 24 | $-15.8M | $52.3M |
毛利率EXASSAM
| Q1 26 | — | 46.4% | ||
| Q4 25 | 70.1% | 43.5% | ||
| Q3 25 | 68.6% | 50.8% | ||
| Q2 25 | 69.3% | 49.8% | ||
| Q1 25 | 70.8% | 48.3% | ||
| Q4 24 | 69.0% | 39.9% | ||
| Q3 24 | 69.4% | 46.3% | ||
| Q2 24 | 69.8% | 46.0% |
营业利润率EXASSAM
| Q1 26 | — | 12.4% | ||
| Q4 25 | -9.4% | -8.6% | ||
| Q3 25 | -3.0% | 11.5% | ||
| Q2 25 | -0.3% | 14.0% | ||
| Q1 25 | -13.6% | 7.4% | ||
| Q4 24 | -122.8% | -13.9% | ||
| Q3 24 | -5.6% | 7.6% | ||
| Q2 24 | -3.8% | 12.2% |
净利率EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | -5.8% | ||
| Q3 25 | -2.3% | 8.6% | ||
| Q2 25 | -0.1% | 10.3% | ||
| Q1 25 | -14.3% | 5.4% | ||
| Q4 24 | -121.2% | -9.6% | ||
| Q3 24 | -5.4% | 5.5% | ||
| Q2 24 | -2.3% | 9.0% |
每股收益（稀释后）EXASSAM
| Q1 26 | — | $2.16 | ||
| Q4 25 | $-0.45 | $-1.97 | ||
| Q3 25 | $-0.10 | $4.25 | ||
| Q2 25 | $-0.01 | $5.45 | ||
| Q1 25 | $-0.54 | $2.16 | ||
| Q4 24 | $-4.69 | $-3.23 | ||
| Q3 24 | $-0.21 | $2.86 | ||
| Q2 24 | $-0.09 | $4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $164.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $682.6M |
| 总资产 | $5.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSAM
| Q1 26 | — | $164.1M | ||
| Q4 25 | $964.7M | $223.4M | ||
| Q3 25 | $1.0B | $250.5M | ||
| Q2 25 | $858.4M | $212.4M | ||
| Q1 25 | $786.2M | $152.5M | ||
| Q4 24 | $1.0B | $211.8M | ||
| Q3 24 | $1.0B | $255.6M | ||
| Q2 24 | $946.8M | $219.3M |
股东权益EXASSAM
| Q1 26 | — | $682.6M | ||
| Q4 25 | $2.4B | $846.3M | ||
| Q3 25 | $2.5B | $911.0M | ||
| Q2 25 | $2.5B | $912.3M | ||
| Q1 25 | $2.4B | $897.0M | ||
| Q4 24 | $2.4B | $916.2M | ||
| Q3 24 | $3.2B | $1.0B | ||
| Q2 24 | $3.2B | $1.0B |
总资产EXASSAM
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.9B | $1.2B | ||
| Q3 25 | $5.9B | $1.2B | ||
| Q2 25 | $5.8B | $1.3B | ||
| Q1 25 | $5.7B | $1.2B | ||
| Q4 24 | $5.9B | $1.3B | ||
| Q3 24 | $6.7B | $1.4B | ||
| Q2 24 | $6.7B | $1.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $39.9M | ||
| Q3 25 | $219.9M | $101.8M | ||
| Q2 25 | $89.0M | $126.5M | ||
| Q1 25 | $30.8M | $1.9M | ||
| Q4 24 | $47.1M | $41.9M | ||
| Q3 24 | $138.7M | $115.9M | ||
| Q2 24 | $107.1M | $96.0M |
自由现金流EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $22.1M | ||
| Q3 25 | $190.0M | $89.2M | ||
| Q2 25 | $46.7M | $112.2M | ||
| Q1 25 | $-365.0K | $-8.0M | ||
| Q4 24 | $10.7M | $18.4M | ||
| Q3 24 | $112.6M | $99.2M | ||
| Q2 24 | $71.2M | $75.6M |
自由现金流率EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 5.7% | ||
| Q3 25 | 22.3% | 16.6% | ||
| Q2 25 | 5.8% | 19.1% | ||
| Q1 25 | -0.1% | -1.8% | ||
| Q4 24 | 1.5% | 4.6% | ||
| Q3 24 | 15.9% | 16.4% | ||
| Q2 24 | 10.2% | 13.1% |
资本支出强度EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 4.6% | ||
| Q3 25 | 3.5% | 2.3% | ||
| Q2 25 | 5.2% | 2.4% | ||
| Q1 25 | 4.4% | 2.2% | ||
| Q4 24 | 5.1% | 5.8% | ||
| Q3 24 | 3.7% | 2.8% | ||
| Q2 24 | 5.1% | 3.5% |
现金转化率EXASSAM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | — | 2.09× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.46× | ||
| Q2 24 | — | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SAM
暂无分部数据
